NuCana plc Stock

NCNA

US67022C3043

Biotechnology & Medical Research

Market Closed - Nasdaq 00:00:00 03/10/2026 +04			5-day change	1st Jan Change
1.090 ^USD	-6.84%		-14.84%	-69.72%

09-25	European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading; Down for Week	MT
09-18	European Equities Traded in the US as American Depositary Receipts Drop in Friday Trading	MT

Analysts' recommendations: NuCana plc

15/10/24	Truist Slashes Price Target on NuCana to $20 From $150 Amid Discontinuation of NUC-3373, Keeps Buy Rating	MT
30/08/24	Top Midday Decliners	MT
30/08/24	William Blair Downgrades NuCana to Market Perform From Outperform	MT
21/11/22	Oppenheimer Trims NuCana's Price Target to $4 From $5, Maintains Outperform Rating	MT
22/09/22	Jefferies & Co. Adjusts NuCana's Price Target to $3 From $21, Keeps Buy Rating	MT

More recommendations

Managers and Directors: NuCana plc

Manager	Title	Age	Since
Hugh Griffith CEO	Chief Executive Officer	58	20/03/2008
Ian Webster DFI	Director of Finance/CFO	-	01/01/2019
Michelle Myers CTO	Chief Tech/Sci/R&D Officer	-	01/01/2022

Director	Title	Age	Since
Hugh Griffith BRD	Director/Board Member	58	20/03/2008
Martin Mellish BRD	Director/Board Member	68	14/12/2009
Cyrille Leperlier BRD	Director/Board Member	72	01/05/2018

More insiders

NuCana plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is focused on developing treatment outcomes for patients with cancer by applying its ProTide technology. The Company's pipeline includes NUC-7738 and NUC-3373. NUC-7738 is an anti-cancer agent that disrupts Ribonucleic acid (RNA) polyadenylation, profoundly impacts gene expression in cancer cells and targets multiple aspects of the tumor microenvironment. NUC-7738 is in the Phase II part of a Phase I/II study which is evaluating NUC-7738 as a monotherapy in patients with advanced solid tumors and in combination with pembrolizumab in patients with melanoma. NUC-3373 is a chemical entity derived from the nucleoside analog 5-fluorouracil, a chemotherapy agent. NUC-3373 is being evaluated in a Phase Ib/II modular study (NuTide:303) of NUC-3373 in combination with the PD-1 inhibitor pembrolizumab for patients with advanced solid tumors and in combination with docetaxel for patients with lung cancer.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
02/10/26	$1.090	-6.84%	326,012
01/10/26	$1.170	-13.33%	804,731
30/09/26	$1.350	+11.57%	3,304,323
29/09/26	$1.210	-6.20%	24,811
28/09/26	$1.290	+0.78%	23,674

Delayed Quote Nasdaq

More quotes

Annual profits - Rate of surprise

Company calendar

Market Cap	3.55M 3.15M 2.94M 2.68M 5.06M 341M 5.11M 35.63M 13.81M 174M 13.33M 13.04M 560M	P/E 2024	-0.15x	P/E 2025	-0.2x
Enterprise Value	-20.02M -17.79M -16.61M -15.14M -28.55M -1.93B -28.81M -201M -77.87M -984M -75.18M -73.55M -3.16B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	99%	Yield 2024 *	-	Yield 2025	-

09-25	European Equities Traded in the US as American Depositary Receipts Edge Higher in Friday Trading; Down for Week	MT
09-18	European Equities Traded in the US as American Depositary Receipts Drop in Friday Trading	MT
09-03	European Equities Traded in the US as American Depositary Receipts Edge Higher in Thursday Trading	MT
09-01	European Equities Traded in the US as American Depositary Receipts Edge Higher in Tuesday Trading	MT
08-31	European Equities Traded in the US as American Depositary Receipts Edge Lower in Monday Trading	MT
08-27	European Equities Traded in the US as American Depositary Receipts Track Lower in Thursday Trading	MT
08-24	European Equities Traded in the US as American Depositary Receipts Track Slightly Lower in Monday Trading	MT
08-20	European Equities Traded in the US as American Depositary Receipts Rise in Thursday Trading	MT
08-17	European Equities Traded in the US as American Depositary Receipts Open Week Higher in Monday Trading	MT
08-14	European Equities Traded in the US as American Depositary Receipts Track Lower in Friday Trading	MT
08-14	NuCana plc Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026	CI
08-12	European Equities Traded in the US as American Depositary Receipts Edge Lower in Wednesday Trading	MT
08-07	European Equities Traded in the US as American Depositary Receipts Rise in Friday Trading	MT

09-30	NuCana Announces Grant of Composition-of-Matter Patent for NUC-7738 in Europe	AQ
08-14	NuCana Reports Second Quarter 2026 Financial Results and Provides Business Update	AQ
06-01	NuCana Appoints Ian Webster as Chief Financial Officer	AQ
05-15	NuCana Reports First Quarter 2026 Financial Results and Provides Business Update	AQ
05-06	NuCana : Notice of AGM - 2026	PU

1 day	-6.84%
1 week	-14.84%
Current month	-19.26%
1 month	-21.58%
3 months	-19.85%
6 months	-33.13%
Current year	-69.72%

1 week	0.95	1.44
1 month	0.95	1.44
Current year	0.95	3.81
1 year	0.95	7.22
3 years	0.95	4,051
5 years	0.95	16,598.5
10 years	0.95	160,000

NuCana plc Stock

Stocks

NCNA

US67022C3043

Biotechnology & Medical Research

Valuation: NuCana plc

Chart: NuCana plc

Latest news: NuCana plc

Analysts' recommendations: NuCana plc

Press Releases: NuCana plc

Quotes and Performance

Price Extremes

Managers and Directors: NuCana plc

Latest insider transactions

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Annual profits - Rate of surprise

Date	Insider	Type	Main position	Quantity	% Market Cap.
15/04/26	Theresa Bruce	Free	Chief Operating Officer	132,600,130	-
18/03/26	David Harrison	Other	Head of Translational Medicine	283,984,182	-
18/03/26	Hugh Griffith	Other	Founder	4,352,841,381	-

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
NUCANA PLC	-6.84%	-14.84%	-76.46%	-99.96%	4.7M
WUXI APPTEC CO., LTD.	+4.16%	+3.04%	+49.37%	+94.17%	74.16B
ARGENX SE	-3.11%	-3.53%	+21.92%	+74.60%	57.39B
LONZA GROUP AG	+0.89%	-0.63%	+4.28%	+34.51%	47.64B
REVOLUTION MEDICINES, INC.	+0.36%	+0.81%	+352.17%	+689.61%	44.29B
IQVIA HOLDINGS INC.	-0.96%	-4.50%	+26.36%	+33.18%	42.5B
BEONE MEDICINES AG	-0.20%	-0.77%	+3.74%	+100.60%	40.71B
CELLTRION, INC.	-0.54%	+2.93%	+9.31%	+50.41%	30.97B
WUXI BIOLOGICS (CAYMAN) INC.	-2.68%	+2.92%	+29.63%	+19.50%	28.53B
BIONTECH SE	+0.05%	-1.64%	-7.28%	-14.06%	24.34B
Average	-0.89%	-2.01%	+41.30%	+98.26%	39.05B
Weighted average by Cap.	+0.12%	-0.84%	+58.76%	+129.91%

	2024	2025
Net sales	-	-
Net income	-19M -16.88M -15.75M -14.36M -27.08M -1.83B -27.33M -191M -73.88M -934M -71.32M -69.78M -3B	-29.35M -26.08M -24.34M -22.19M -41.84M -2.82B -42.23M -295M -114M -1.44B -110M -108M -4.63B
Net Debt	-6.56M -5.83M -5.44M -4.96M -9.35M -631M -9.44M -65.82M -25.51M -322M -24.63M -24.09M -1.03B	-23.58M -20.95M -19.55M -17.82M -33.61M -2.27B -33.92M -237M -91.68M -1.16B -88.51M -86.59M -3.72B

Markets		Quality
Nasdaq	NCNA	Delayed
CBOE	NCNA	Real-time